Myeloproliferative Neoplasms NFZ — 43 facilities in 38 cities

Myeloproliferative neoplasms are a group of bone marrow disorders with overproduction of blood cells, including polycythemia vera, essential thrombocythemia, and myelofibrosis. The NFZ covers genetic testing for JAK2, CALR, and MPL mutations, bone marrow biopsy, cytoreductive treatment with hydroxyurea and ruxolitinib, and dedicated drug programs. Ongoing hematological monitoring is required.